Q-omics provides the consensus-scored NACAD profile across patient tissues and cancer cell-line models. NACAD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NACAD is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NACAD RNA expression shows 18,353 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where NACAD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACAD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACAD survival associations across molecular data types. NACAD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACAD RNA expression–survival associations across cancer types. High NACAD expression shows unfavorable associations in ACC, LUSC, COAD and MESO, but favorable associations in BRCA and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NACAD RNA expression.
This table summarizes NACAD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NACAD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACAD shows lower tumor expression in COAD, KIRC, UCEC, BRCA and STAD and higher tumor expression in HNSC. The COAD box plot shows higher NACAD RNA expression in normal versus tumor tissue (log2 FC = −1.110, t-test p < 0.001).
This table shows molecular features associated with NACAD in patient tissues and cancer cell lines. In patient samples, NACAD shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NACAD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
